reference/12759324

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12759324

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial
endingPage	3509
issn	1097-0142 0008-543X
issueIdentifier	22
pageRange	3502-3509
publicationName	Cancer
startingPage	3502
bibliographicCitation	Tian YM, Zhao C, Guo Y, Huang Y, Huang SM, Deng XW, Lin CG, Lu TX, Han F. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a phase 2, single-center, randomized controlled trial. Cancer. 2014 Nov 15;120(22):3502–9. doi: 10.1002/cncr.28934. PMID: 25056602.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6765f9a2ea81b86ea62d35fb11adcf60 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_097cd0fa264952d2077d40d45b87ccac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_008df5c4afe0a6d48feddc6e1cdc8019 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f32d1e84b3c2659e0d47b7a8133d829 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2676a0e68734cecffe9dd07565a326f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6d8906d37390e9f790f2e1b457c9468b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb1e20ea825b86207907699c14ffcb0a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6aec988fd22166c5f6ee5ea8b4252324 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c341988e8599008a45820ebade28cd23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1598-9048
date	2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/25056602 https://doi.org/10.1002/cncr.28934
isPartOf	https://portal.issn.org/resource/ISSN/1097-0142 https://portal.issn.org/resource/ISSN/0008-543X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy: A phase 2, single‐center, randomized controlled trial
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D050397Q000009 http://id.nlm.nih.gov/mesh/D009303Q000532 http://id.nlm.nih.gov/mesh/D009364Q000532
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D017211 http://id.nlm.nih.gov/mesh/D011879 http://id.nlm.nih.gov/mesh/D047368 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D009303Q000473 http://id.nlm.nih.gov/mesh/D002277 http://id.nlm.nih.gov/mesh/D009364Q000401 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D002423 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D015999 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D009303Q000401 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000077274
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8596 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6656 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969

Total number of triples: 52.